The C-Reactive Protein Testing Market is expected to grow at a CAGR of 2.21%, reaching a market size of US$2.342 billion in 2030 from US$2.099 billion in 2025.
Tests for C-reactive protein (CRP) measure levels of this protein in the body. An increase in C-reactive protein levels in the body can be attributed to inflammation. The liver produces this protein. Inflammatory diseases and infections are identified and tracked by C-reactive protein tests, which include cancers, cardiovascular disease, arthritis, etc. The tests estimate whether someone is at risk of having a heart attack or stroke.
Cardiovascular diseases (CVDs) have become more prevalent, and as tests are becoming more complex, this market is being driven by these factors. As reported by the WHO, CVDs kill about 17.9 million people each year. Numerous opportunities exist in the market, including the growing application of these tests, point-of-care testing, increased population coverage, and increased healthcare awareness, particularly in developing countries.
The market is also expected to grow due to increased funds provided by the government to academic research institutions and individuals. Market growth is further anticipated to be supported by various initiatives by international organizations, including the WHO and NIH, that aim to prevent and treat chronic disorders such as cancer and cardiovascular diseases.
Globally, the market for C-reactive protein tests will grow because of the rising prevalence of inflammatory disorders, the increasing prevalence of endometriosis in women, and technological advancements in diagnostic tests. A large number of chronic diseases, including lupus, ulcerative colitis, rheumatoid arthritis, and others, are thought to be triggered by chronic inflammation.
According to the Centers for Disease Control and Prevention (CDC) 2016 report, it is estimated that by 2040, approximately 78 million (26%) of US adults aged 18 and up will have arthritis. Furthermore, this market's growth would be challenged by the lack of public awareness.
It is urgently necessary to develop a quick and accurate method for diagnosing cardiovascular diseases, given their high prevalence. CRP can, therefore, be used to detect CVD due to the development of atherosclerosis, in which cholesterol is deposited inside blood vessel walls, leading to inflammation. As a result, CRP levels are higher in patients with cardiovascular disease.
Consequently, these CRP assays can detect low CRP levels, which are sensitive. Because cardiovascular diseases are increasingly prevalent, researchers are likely to pursue evaluations of CRP for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death in the world. There are an estimated 3.8 million males and 3.4 million females who die of coronary heart disease every year. More than 80% of deaths occur in low- and middle-income countries.
Additionally, approximately 356,000 cardiac arrests occur in the U.S. outside of hospitals every year, of which 90% are fatal, according to data from the American Heart Association in 2019. It is for this reason that clinicians are increasingly implementing CRP testing. Hence, these factors combined are causing the cardiovascular diseases segment to grow at a steady pace over the forecast period.
Many research and development projects are conducted by universities and other organizations. For example, a group of researchers from the University of Hong Kong has developed a real-time, flexible sensing device that can directly measure CRP blood levels. With this sensor, inflammation testing is 30 times faster than usual. Incidents such as these are a major factor contributing to the C-reactive protein testing market growth.
Over time, CRP has developed into a flexible diagnostic tool for determining systemic inflammatory disorders. Advances in nanomaterials and electroanalytical chemistry have led to the creation of CRP tests with higher sensitivity and specificity. CRP testing has advanced to include CRP-based enzymatic tests using modern electrochemical biosensors, gradually replacing classical antigen-antibody interactions.
Electrochemical sensors are used in the development of a highly sensitive, portable detection system based on ZnS nanoparticles, metal-oxide-semiconductor field-effect transistor/bipolar junction transistor, aptamer, silicon nanowire, vertical flow immunoassay, field emission transmitter, and other nanomaterials.
Ultrasensitive CRP level analysis should be possible in much less time with future advancements in multidisciplinary approaches. Thus, CRP testing methods for diagnosing systemic inflammatory illnesses would be used by more individuals. New CRP identification chemicals and materials that facilitate the creation of sensing platforms also present a lot of prospects in the CRP testing market.
CRP testing instruments, however, are expensive. High costs will constrain the market during the given period. The lack of qualified professionals in the field will also hinder the market for CRP tests during the given period. In addition, low public awareness about the CRP test, as well as its low specificity in diagnosing a particular disease, are expected to restrain the market’s growth.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2025 | US$2.099 billion |
| Market Size Value in 2030 | US$2.342 billion |
| Growth Rate | CAGR of 2.21% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2025 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segments Covered |
|
| Companies Covered | |
| Regions Covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Customization Scope | Free report customization with purchase |